Ultragenyx Pharmaceutical Inc
For the period ended Dec 31, 2024. Filed Feb 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 19, 2025
RARE$16.41+6.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Net loss | $(569,183) | $(606,639) | $(707,421) |
| Other comprehensive income (loss): | |||
| Foreign currency translation adjustments | (1,044) | 239 | (724) |
| Changes in unrealized gain (loss) on available-for-sale securities | (246) | 6,981 | (4,445) |
| Other comprehensive income (loss): | (1,290) | 7,220 | (5,169) |
| Total comprehensive loss | $(570,473) | $(599,419) | $(712,590) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.